associ
high
mortal
patient
hematolog
malign
hm
sought
determin
whether
allogen
hematopoiet
cell
transplant
allohct
recipi
would
higher
risk
mortal
examin
retrospect
cohort
adult
hm
without
hct
treat
rsv
lrti
n
institut
defin
possibl
rsv
lrti
rsv
detect
upper
respiratori
tract
new
radiolog
infiltr
proven
rsv
lrti
rsv
detect
bal
fluid
new
radiolog
infiltr
immunodefici
score
index
isi
sever
immunodefici
sid
criteria
calcul
hct
recipi
multivari
logist
regress
analys
perform
identifi
independ
risk
factor
associ
allcaus
mortal
result
mortal
high
hm
patient
differ
without
hct
autolog
allohct
recipi
logist
regress
model
separ
multivari
model
show
rsv
diagnosi
neutropenia
ci
p
lymphopenia
ci
p
associ
mortal
proven
lrti
associ
higher
mortal
neutropenia
model
ci
lymphopenia
model
ci
higher
icu
admiss
hct
recipi
high
isi
sever
immunodefici
sid
criteria
associ
higher
allcaus
mortal
mortal
similarli
high
among
hm
patient
without
hct
hct
recipi
highgrad
immunodefici
detect
rsv
bal
fluid
associ
higher
mortal
hematolog
malign
hematopoiet
cell
transplant
lower
respiratori
tract
infect
mortal
respiratori
syncyti
viru
r
e
fe
r
e
n
c
e
infect
respiratori
syncyti
viru
rsv
major
caus
death
immunocompromis
patient
hematolog
malign
hm
without
hematopoiet
cell
transplant
hct
incid
infect
estim
hct
recipi
mortal
rate
lower
respiratori
tract
infect
lrti
reach
new
therapi
strategi
need
improv
outcom
rsv
lrti
immunocompromis
host
rsv
diagnosi
confirm
risk
stratif
hm
patient
critic
given
high
cost
therapi
aerosol
ribavirin
high
mortal
rate
lrti
prior
studi
identifi
lymphopenia
neutropenia
rsv
detect
lower
respiratori
sampl
import
risk
factor
mortal
lrti
recognit
individu
high
risk
advers
outcom
could
improv
prompt
deliveri
ribavirin
treatment
may
reduc
mortal
morbid
previous
develop
immunodefici
score
index
base
clinic
characterist
laboratori
paramet
standard
risk
stratif
practic
allogen
hct
allohct
recipi
rsv
upper
respiratori
tract
infect
urti
group
high
risk
advers
outcom
rsv
infect
hypothes
among
hm
patient
without
hct
autolog
hct
autohct
allohct
recipi
allohct
recipi
would
highest
risk
mortal
hypothes
isol
rsv
respiratori
pathogen
lower
respiratori
tract
among
patient
underw
fiberopt
bronchoscopi
would
associ
higher
mortal
demonstr
parainfluenza
viral
infect
also
sought
determin
whether
sever
immunodefici
hct
recipi
determin
immunodefici
score
index
isi
sever
immunodefici
sid
criteria
predict
mortal
rsv
lrti
conduct
retrospect
review
adult
type
leukemia
lymphoma
multipl
myeloma
hm
underw
autoor
allohct
year
age
older
rsv
infect
care
univers
texa
md
anderson
cancer
center
patient
identifi
prospectivelymaintain
infect
control
databas
viral
infect
collect
data
patient
demograph
underli
malign
immun
statu
diagnosi
antivir
therapi
thorac
imag
microbiolog
data
also
collect
data
outcom
includ
hospit
admiss
intens
care
unit
icu
admiss
mechan
ventil
allcaus
mortal
day
studi
approv
institut
review
board
accord
helsinki
declar
world
medic
associ
waiver
inform
consent
grant
defin
rsv
lrti
microbiolog
confirm
rsv
nasal
wash
swab
bal
fluid
b
new
infiltr
cxr
chest
ct
within
day
microbiolog
confirm
microbiolog
confirm
perform
use
either
shell
vial
cultur
direct
immunofluoresc
antibodi
test
per
institut
practic
time
stratifi
rsv
lrti
possibl
proven
rsv
lrti
defin
possibl
rsv
lrti
rsv
detect
upper
respiratori
tract
new
pulmonari
infiltr
chest
imag
suggest
viral
etiolog
proven
rsv
lrti
patient
rsv
detect
lower
respiratori
tract
obtain
bal
new
pulmonari
infiltr
chest
imag
suggest
viral
etiolog
direct
immunofluoresc
antibodi
test
less
sensit
pcr
detect
rsv
possibl
patient
detect
rsv
bal
fluid
proven
rsv
lrti
therefor
patient
rsv
detect
bal
also
consid
possibl
rsv
lrti
bal
copathogen
defin
nonrsv
organ
viru
bacteria
fungu
known
caus
pneumonia
human
defin
neutropenia
absolut
neutrophil
count
cellsmm
lymphopenia
absolut
lymphocyt
count
cellsmm
consid
patient
receiv
ribavirin
therapi
prior
diagnosi
lrti
receiv
ribavirin
urti
stage
patient
receiv
ribavirin
therapi
time
diagnosi
lrti
receiv
ribavirin
lrti
stage
radiograph
imag
independ
review
two
pulmonologist
ev
discrep
resolv
mutual
agreement
exclud
patient
resolv
infiltr
known
prior
lrti
clinic
volum
overload
assess
echocardiographi
right
heart
catheter
respons
diuret
prior
patient
imag
avail
independ
review
case
radiologist
interpret
document
medic
record
use
bronchoscopi
perform
dedic
endoscopi
suit
supervis
experienc
pulmonologist
result
bronchial
wash
exclud
minim
contamin
upper
respiratori
tract
patient
possibl
rsv
lrti
undergo
bronchoscopi
n
reason
perform
bronchoscopi
record
avail
tabl
hct
recipi
score
use
isi
sid
criteria
time
rsv
lrti
isi
rang
isi
score
calcul
previous
describ
point
given
anc
cellsmm
alc
cellsmm
point
age
year
point
given
myeloabl
condit
regimen
graftversushost
diseas
corticosteroid
within
day
rsv
infect
recent
preengraft
allohct
hct
recipi
stratifi
lowrisk
isi
moder
risk
isi
highrisk
isi
strata
sid
criteria
classifi
hct
recipi
three
strata
moder
immunodefici
mid
sever
immunodefici
sid
sever
immunodefici
vsid
mid
defin
hct
month
prior
lrti
leukocyt
count
cellsmm
alc
cellsmm
sid
defin
hct
month
prior
lrti
tcell
deplet
month
prior
lrti
bcell
deplet
month
prior
lrti
graftversushost
diseas
grade
leukocyt
count
cellsmm
alc
cell
mm
immunoglobulin
count
gl
vsid
defin
sid
risk
factor
present
time
lrti
descript
statist
calcul
demograph
clinic
therapeut
data
categor
variabl
compar
use
chisquar
fisher
exact
test
continu
variabl
compar
use
oneway
analysi
varianc
multivari
logist
regress
analys
perform
identifi
independ
risk
factor
associ
allcaus
mortal
patient
follow
entir
day
outcom
rightcensor
variabl
enter
multivari
model
backward
elimin
use
includ
variabl
identifi
patient
met
inclus
exclus
criteria
underw
bronchoscopi
bal
tabl
median
age
year
rang
year
femal
patient
without
hct
autohct
allohct
possibl
rsv
lrti
diagnos
patient
proven
rsv
lrti
patient
allohct
recipi
younger
autohct
recipi
like
multipl
myeloma
underli
malign
corticosteroid
among
hct
recipi
median
time
hct
lrti
day
interquartil
rang
day
patient
without
hct
like
receiv
chemotherapi
within
month
rsv
lrti
neutropenia
lymphopenia
less
like
receiv
ribavirin
therapi
rsv
alon
detect
bal
sampl
rsv
concurr
nonrsv
respiratori
pathogen
detect
nonrsv
pathogen
alon
detect
pathogen
detect
major
patient
undergo
bronchoscopi
refer
procedur
discret
primari
oncologist
transplant
physician
tabl
hospit
time
rsv
common
among
patient
cohort
although
patient
without
hct
less
like
hospit
tabl
differ
rate
icu
admiss
mechan
ventil
mortal
mortal
patient
without
hct
allohct
recipi
autohct
recipi
mortal
high
across
group
patient
proven
lrti
like
admit
icu
vs
p
die
day
vs
p
day
vs
p
lrti
onset
tabl
univari
logist
regress
model
neutropenia
rsv
diagnosi
odd
ratio
confid
interv
ci
lymphopenia
rsv
diagnosi
ci
proven
lrti
ci
predict
mortal
tabl
lymphopenia
neutropenia
exhibit
high
degre
collinear
creat
two
multivari
model
model
includ
neutropenia
lymphopenia
candid
variabl
final
model
model
includ
lymphopenia
neutropenia
candid
variabl
final
model
model
adjust
neutropenia
proven
lrti
ribavirin
therapi
allohct
recipi
higher
risk
mortal
patient
without
hct
autohct
recipi
adjust
ci
p
kaplanmei
surviv
curv
shown
patient
hm
hct
allohct
recipi
autohct
recipi
figur
signific
differ
surviv
group
p
kaplanmei
curv
demonstr
patient
proven
lrti
lower
surviv
rate
possibl
lrti
p
figur
subgroup
analys
reveal
signific
differ
surviv
curv
patient
undergo
bronchoscopi
neg
bal
nonrsv
pathogen
detect
bal
rsv
detect
bal
rsv
addit
pathogen
detect
bal
p
figur
patient
undergo
bronchoscopi
similar
surviv
neg
bal
nonrsv
pathogen
detect
bal
patient
rsv
addit
pathogen
detect
bal
fluid
lowest
surviv
though
like
due
small
sampl
size
signific
differ
patient
rsv
alon
detect
bal
fluid
p
figur
surviv
rate
significantli
differ
patient
start
ribavirin
therapi
urti
stage
infect
ribavirin
therapi
lrti
stage
infect
ribavirin
therapi
p
figur
calcul
isi
grade
sid
criteria
hct
recipi
measur
associ
mortal
highrisk
individu
identifi
isi
higher
risk
mortal
lowrisk
individu
ci
p
observ
high
mortal
rsv
lrti
hm
patient
without
hct
howev
differ
mortal
hm
patient
without
hct
allohct
autohct
recipi
lymphopenia
neutropenia
independ
predictor
mortal
furthermor
detect
rsv
bal
fluid
defin
proven
rsv
lrti
associ
higher
allcaus
mortal
day
higher
rate
icu
admiss
highgrad
immunodefici
defin
isi
grade
sid
criteria
associ
higher
rate
allcaus
mortal
consist
studi
viral
lrti
found
mortal
hm
patient
without
hct
high
mortal
rate
across
group
similar
studi
hm
patient
rsv
lrti
patient
acut
myeloid
leukemia
institut
patient
rsv
lrti
die
contemporari
cohort
hct
recipi
rsv
lrti
overal
mortal
rang
allohct
recipi
often
highrisk
underli
malign
requir
immunosuppress
compar
autohct
recipi
howev
found
mortal
high
hm
patient
regardless
hct
statu
similar
group
found
differ
risk
mortal
possibl
allohct
recipi
higher
risk
death
adjust
presenc
neutropenia
studi
definit
prove
previou
studi
show
neutropenia
lymphopenia
associ
higher
risk
death
hct
recipi
rsv
lrti
separ
multivari
model
found
ta
b
l
e
impact
immunodefici
mortal
rsv
lrti
hct
recipi
lymphopenia
neutropenia
associ
mortal
lymphopenia
associ
increas
progress
urti
lrti
wellknown
marker
mortal
similarli
neutropenia
independ
associ
progress
rsv
lrti
convers
normal
lymphocyt
count
associ
low
rate
progress
lrti
furthermor
found
highgrad
immunodefici
defin
isi
sid
criteria
highlyassoci
mortal
whether
use
isi
sid
criteria
highgrad
immunodefici
associ
allcaus
mortal
around
rsv
lrti
similar
prior
studi
initi
develop
cohort
isi
consist
allohct
recipi
rsv
lrti
urti
mortal
high
among
receiv
ribavirin
urti
stage
progress
lrti
day
among
present
lrti
receiv
ribavirin
diagnosi
day
importantli
isi
develop
cohort
allohct
recipi
design
predict
progress
rsv
urti
lrti
current
studi
show
isi
less
use
autohct
recipi
particularli
sinc
certain
criteria
graftversushost
diseas
may
applic
similarli
studi
patient
rsv
lrti
found
highrisk
patient
identifi
isi
rsvassoci
mortal
high
isi
also
associ
high
mortal
influenza
infect
agreement
studi
find
associ
corticosteroid
use
time
lrti
mortal
corticosteroid
use
use
part
immunodefici
score
index
tool
predict
risk
progress
rsv
urti
lrti
allohct
recipi
independ
associ
progress
rsv
lrti
howev
mix
cohort
patient
hmpv
rsv
lrti
corticosteroid
use
hypoxemia
associ
increas
mortal
similarli
corticosteroid
use
diagnosi
rsv
infect
associ
higher
incid
hypoxemia
dosedepend
fashion
futur
prospect
studi
necessari
investig
time
dosag
corticosteroid
administr
relationship
mortal
rsv
lrti
highrisk
hm
patient
rsv
infect
particularli
hct
recipi
consid
candid
ribavirin
therapi
urti
stage
earli
treatment
may
prevent
lrti
find
signific
differ
mortal
patient
start
riba
sever
limit
find
retrospect
cohort
analysi
find
requir
confirm
prospect
studi
patient
refer
bronchoscopi
possibl
rsv
lrti
may
less
sick
result
referr
bia
howev
patient
refer
sick
undergo
bronchoscopi
would
bia
result
toward
null
hypothesi
use
viral
cultur
direct
immunofluoresc
antibodi
test
detect
rsv
respiratori
viral
pathogen
institu
associ
isi
mortal
autohct
recipi
interpret
caution
sinc
isi
develop
quantifi
immunodefici
autohct
recipi
small
size
cohort
small
number
death
n
could
measur
interact
proven
rsv
lrti
immunodefici
score
find
need
replic
larger
prospect
cohort
conclus
found
mortal
high
hm
patient
without
hct
develop
rsv
lrti
neutropenia
lymphopenia
predict
mortal
addit
highrisk
isi
vsid
rsv
diagnosi
associ
higher
mortal
furthermor
detect
rsv
bal
fluid
associ
higher
allcaus
mortal
without
rsv
detect
bal
routin
calcul
immunodefici
score
may
improv
risk
stratif
hct
recipi
data
bal
may
complement
immunodefici
score
use
identifi
patient
rsv
infect
respiratori
virus
greatest
risk
death
patient
would
ideal
candid
earli
ribavirin
therapi
clinic
trial
new
investig
drug
